Valeant Unveils $2B Buyback Plan After Failed Allergan Deal

Canadian drug giant Valeant Pharmaceuticals International Inc. has approved the repurchase of $2 billion in securities, outlining the plans to boost shareholder value Thursday — just days after its $55 billion bid to buy Botox maker Allergan Inc. fell through.